Category: Johnson & JohnsonSyndicate content

Feds indict ex-Acclarent execs | The week in medtech M&A

April 15, 2015 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Feds slap former Acclarent execs with fraud charges; Zimmer extends deadline for $13B Biomet deal; Big data: IBM enlists Medtronic, J&J, Apple in major healthcare push

Feds slap former Acclarent execs with fraud charges

April 13, 2015 by Brad Perriello

Big data: IBM enlists Medtronic, J&J, Apple in major healthcare push

April 14, 2015 by Brad Perriello

IBM unveils a major push to use 'Big Data' and its Watson supercomputer to drive healthcare research and personalized medicine, enlisting Medtronic, Johnson & Johnson and Apple to help.

IBM enlists Medtronic, J&J, Apple in major healthcare push

Pharma the lone Q1 bright spot for J&J

April 14, 2015 by Brad Perriello

The strong dollar pares a 13% chunk out Johnson & Johnson's 1st-quarter sales, prompting a lowered earnings outlook, but the healthcare giant still manages to beat Wall Street's estimate.

Pharma the lone bright spot for J&J's Q1 sales

BAX drops FloSeal case against J&J | Medtech legal news for the week of April 13, 2015

April 13, 2015 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Baxter drops FloSeal case against J&J; Feds: We got $119m in fraud penalties from medtech companies last year; Insurer, DJO Global settle pain pump suit

Baxter drops FloSeal case against J&J

April 6, 2015 by Brad Perriello

YYmeta

Ichor Medical inks $85m drug-device deal with J&J

April 13, 2015 by Brad Perriello

Ichor Medical said it inked an $85 million development deal with Johnson & Johnson's Janssen Pharmaceuticals division for a DNA-based hepatitis-B vaccine using Ichor's TriGrid electroporation technology.

Ichor Medical inks drug-device deal with J&J

Feds slap former Acclarent execs with fraud charges

April 13, 2015 by Brad Perriello

Federal prosecutors charge former Acclarent CEO William Facteau and ex-sales veep Patrick Fabian with fraud and conspiracy for allegedly marketing a sinus device for off-label uses.

Feds slap former Acclarent execs with fraud charges

Federal prosecutors last week leveled conspiracy and fraud charges against 2 former executives of Acclarent for an alleged off-label marketing scheme for the Relieva Stratus microflow spacer.

J&J's Ethicon wins expanded clearance for Evarrest patch

April 6, 2015 by Mark Hollmer

Johnson & Johnson's Ethicon division wins FDA clearance to use its Evarrest fibrin sealant patch during adult liver surgery as a tool to help control bleeding.

J&J's Ethicon wins expanded clearance for Evarrest patch

Ethicon won an expanded indication for its Evarrest fibrin sealant patch to include its use it as a tool to help control bleeding during adult liver surgery.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.